Marinomed Biotech AG | WebDisclosure

Switch to English

10069	Sociétés
205836	Mots-clés
136102	Articles
109144	Communiqués

Accueil
Sociétés
Marinomed Biotech AG

COMMUNIQUÉ DE PRESSE

publié le 16/09/2025 à 15:22, il y a 6 mois 7 jours

EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Marinomed Biotech AG resolves capital increase by issuing 61.607 bearer shares at EUR 17,50 per share, excluding statutory subscription rights

Capital Increase Marinomed Biotech AG Subscription Rights Bearer Shares EUR 17,50
BRÈVE

publiée le 01/09/2025 à 12:01, il y a 6 mois 22 jours

Marinomed Biotech AG obtient un accord d'émission d'obligations convertibles de 2,5 millions d'euros

Financement Stratégie D'investissement Droits Des Actionnaires Marinomed Biotech Obligation Convertible
BRÈVE

publiée le 01/09/2025 à 12:01, il y a 6 mois 22 jours

Marinomed Biotech AG Secures EUR 2.5 Million Convertible Bond Agreement

Financing Investment Strategy Shareholder Rights Convertible Bond Marinomed Biotech
COMMUNIQUÉ DE PRESSE

publié le 01/09/2025 à 11:56, il y a 6 mois 22 jours

EQS-Adhoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Marinomed Biotech AG announces agreement on key terms for a secured EUR 2.5mn convertible bond issue, including interest rate and conversion price

Marinomed Biotech AG Convertible Bond Secured EUR 2.5mn Key Terms
BRÈVE

publiée le 30/06/2025 à 12:56, il y a 8 mois 23 jours

Marinomed Biotech AG : Perspectives positives dans un contexte de redressement stratégique

Restructuration Financière Marinomed Biotech AG Innovation Biotechnologique Plateforme Marinosolv® Développement Budesolv
BRÈVE

publiée le 30/06/2025 à 12:56, il y a 8 mois 23 jours

Marinomed Biotech AG: Positive Outlook Amidst Strategic Turnaround

Marinomed Biotech AG Financial Restructuring Biotech Innovation Marinosolv® Platform Budesolv Development
COMMUNIQUÉ DE PRESSE

publié le 30/06/2025 à 12:51, il y a 8 mois 23 jours

Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Marinomed Biotech AG with a Buy rating and EUR 50.00 price target. Details of the company's dual business model and lead candidate, Budesolv, are highlighted

First Berlin Equity Research BUY Rating Marinomed Biotech AG Biotech Company Dual Business Model
BRÈVE

publiée le 06/06/2025 à 15:25, il y a 9 mois 17 jours

Marinomed Biotech AG Partners to Launch Budesolv in Switzerland

International Expansion Marinomed Biotech AG Milestone Payments Pharma Partnership Budesolv Switzerland
BRÈVE

publiée le 06/06/2025 à 15:25, il y a 9 mois 17 jours

Marinomed Biotech AG s'associe pour lancer Budesolv en Suisse

Expansion Internationale Marinomed Biotech AG Paiements D'étape Partenariat Pharmaceutique Budesolv Suisse
COMMUNIQUÉ DE PRESSE

publié le 06/06/2025 à 15:20, il y a 9 mois 17 jours

Marinomed Biotech AG announces partnership for Budesolv in Switzerland
Marinomed Biotech AG announces partnership with Swiss pharmaceutical company for the development and marketing of Budesolv in Switzerland, enabling milestone payments and royalties

Pharmaceutical Company Partnership Switzerland Marinomed Biotech AG Budesolv

Les Echos

Publié le 23/03/2026 à 19:08, il y a 2 heures 39 minutes

Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Publié le 23/03/2026 à 19:08, il y a 2 heures 39 minutes

Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Publié le 23/03/2026 à 18:37, il y a 3 heures 10 minutes

ALTAREA : Déclaration d’opérations sur actions propres
Publié le 23/03/2026 à 17:45, il y a 4 heures 2 minutes

ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Publié le 23/03/2026 à 17:45, il y a 4 heures 2 minutes

En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 23/03/2026 à 21:18, il y a 29 minutes

Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Publié le 23/03/2026 à 14:05, il y a 7 heures 42 minutes

Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Publié le 23/03/2026 à 14:00, il y a 7 heures 47 minutes

BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Publié le 23/03/2026 à 13:05, il y a 8 heures 42 minutes

SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Publié le 23/03/2026 à 12:32, il y a 9 heures 15 minutes

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%

Voir tout ACCESSWIRE

EQS Group

Publié le 23/03/2026 à 21:05, il y a 42 minutes

Abivax annonce ses résultats financiers pour l’exercice 2025 et fait le point sur l’avancement de ses activités
Publié le 23/03/2026 à 21:05, il y a 42 minutes

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Publié le 23/03/2026 à 21:00, il y a 47 minutes

Persistent Appoints Ruchi Kulhari as Executive Vice President - Enterprise Strategy & Execution
Publié le 23/03/2026 à 20:55, il y a 52 minutes

Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Publié le 23/03/2026 à 20:23, il y a 1 heure 24 minutes

Full Year 2025 Financial Results